H.C. Wainwright lifts Corcept stock target to $115 on drug outlook
H.C. Wainwright increased its price target on Corcept Therapeutics (NASDAQ:CORT) shares to $115 from the previous $80, while ...
H.C. Wainwright Sticks to Its Buy Rating for UR-Energy (URG)
In a report released on February 7, Heiko Ihle from H.C. Wainwright reiterated a Buy rating on UR-Energy (URG – Research Report), with a price ...
HC Wainwright maintains $18 target on Enanta shares, affirms Buy
H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its ...
NextTrip price target raised to $5 from $2.50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on NextTrip (NTRP) to $5 from $2.50 and keeps a Neutral rating on the shares after the company ...
Corbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...
Oruka Therapeutics’ (ORKA) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) in a report released on ...
PepGen price target lowered to $16 from $26 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on PepGen (PEPG) to $16 from $26 and keeps a Buy rating on the shares after the company shared the safety reports from the CONNECT1-EDO51, the Phase 2, ...
Nasdaq8d
HC Wainwright & Co. Initiates Coverage of CRISPR Therapeutics (LSE:0VRQ) with Buy Recommendation
Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (LSE:0VRQ) with a Buy recommendation. There are 575 funds or institutions reporting positions ...